Chris Martin, Co-Founder of ADC Therapeutics, Leaves CEO Seat for Industry Specialist Ameet Mallik MyPharma Editions

Posted on Tuesday, May 10, 2022

ADC Therapeutics, a biotechnology company developing next-generation targeted antibody-drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer.

dr. Martin will serve on the board of directors as a non-executive member and chair the Science and Technology Committee. He will also act as an advisor to the company for the next three months to ensure a smooth transition. ADC Therapeutics is pleased to announce the appointment of Ameet Mallik as President and Chief Executive Officer. Mr. Mallik will work in ADC Therapeutics’ New Providence, New Jersey office.

“Since I co-founded ADC Therapeutics in 2011, I have been privileged to take our proprietary ADC technology from discovery to the lab and our first FDA approval of ZYNLONTA®,” said Dr. Martin. “The company has grown from a privately held start-up to a New York Stock Exchange listed company with more than 300 employees that provides a commercial product that addresses the unmet need of patients with diffuse large B-cell lymphoma. company includes the Cami antibody, which is progressing towards a Biologics License Application (BLA), five promising programs in development in solid tumors, a robust ADC platform and a strong R&D pipeline. of ZYNLONTA was a particularly important moment for me. Knowing that the company and its pipeline are in an excellent position, I am very pleased to pass the baton to Ameet Mallik, who has proven commercial oncology experience and proven leadership skills to take the company to to bring the next growth chapter.I look forward to working with Ameet to ensure a so smooth transition and to continue to manage the company by serving on the board of directors. †

Ameet Mallik’s pharmaceutical career spans 16 years at Novartis, most recently as Executive Vice President and Head of US Oncology. Prior to that, he held several leadership roles at Novartis Oncology, including Director of Global Marketing, Value and Access and Director of Latin America and Canada. He was also Global Head of Biopharmaceuticals and Oncology Injectables at Sandoz, a division of Novartis Group, and Head of Global Strategic Planning at Novartis Pharmaceuticals. Prior to Novartis, Mr. Mallik was a Managing Partner at McKinsey & Company. Most recently, Mr. Mallik was the CEO of Rafael Holdings, a biotech company dedicated to the development of oncology therapies and immunotherapies. He sits on the boards of directors of Atara Biotherapeutics and Rafael Holdings. Mr. Mallik holds an MBA from The Wharton School at the University of Pennsylvania, and an MS in Biotechnology and BS in Chemical Engineering from Northwestern University.

Mr Mallik said: “I am excited to join the ADC Therapeutics team and take the company forward from its strong foundation. I was drawn to the company because of its great team and rich culture, its validated technology platform, its differentiated commercial product ZYNLONTA, its portfolio of promising assets and its impressive search engine.What Dr. Martin and the team at ADC Therapeutics have achieved in such a short time since the Society’s inception in 2011 is truly remarkable.It is a privilege to lead the company through its next phase of growth, which will include the opportunity to create lasting value for all of our stakeholders.”

“On behalf of the Board of Directors, I would like to sincerely thank Chris for his many contributions to ADC Therapeutics over the past 11 years. His two decades of pioneering experience in the ADC industry have been instrumental in the company’s growth, and he will be a valuable asset if he remains on the board,” said Ron Squarer, Chairman of the Board of Directors. board of ‘ADC Therapeutics. “I am delighted to welcome Ameet Mallik to his role as Chief Executive Officer. At this critical juncture in the company’s transition to a fully integrated research, development and commercial organization, I am confident that Mr. Mallik will lead ADC Therapeutics to deliver breakthrough new therapies to cancer patients. †

Source and image: ADC Therapeutics

Leave a Comment